Celldex Therapeutics (CLDX) EBITDA Margin (2016 - 2025)
Historic EBITDA Margin for Celldex Therapeutics (CLDX) over the last 16 years, with Q2 2025 value amounting to 7784.79%.
- Celldex Therapeutics' EBITDA Margin fell 63313900.0% to 7784.79% in Q2 2025 from the same period last year, while for Sep 2025 it was 8694.42%, marking a year-over-year decrease of 71815500.0%. This contributed to the annual value of 2248.68% for FY2024, which is 2236700.0% down from last year.
- According to the latest figures from Q2 2025, Celldex Therapeutics' EBITDA Margin is 7784.79%, which was down 63313900.0% from 7703.88% recorded in Q1 2025.
- Over the past 5 years, Celldex Therapeutics' EBITDA Margin peaked at 384.14% during Q2 2021, and registered a low of 22412.88% during Q2 2022.
- For the 5-year period, Celldex Therapeutics' EBITDA Margin averaged around 7172.01%, with its median value being 5201.99% (2021).
- Per our database at Business Quant, Celldex Therapeutics' EBITDA Margin crashed by -220287500bps in 2022 and then surged by 140089400bps in 2025.
- Celldex Therapeutics' EBITDA Margin (Quarter) stood at 6228.14% in 2021, then surged by 75bps to 1557.04% in 2022, then surged by 34bps to 1019.92% in 2023, then tumbled by -309bps to 4175.83% in 2024, then tumbled by -86bps to 7784.79% in 2025.
- Its last three reported values are 7784.79% in Q2 2025, 7703.88% for Q1 2025, and 4175.83% during Q4 2024.